ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2025)

ProQR Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability fell 4.8% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (down 4.8% YoY), while the FY2025 annual figure was $3.0 million, down 4.8% from the prior year.
• Non-Current Deferred Tax Liability came in at $3.0 million for Q4 2025 at ProQR Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.0 million in Q4 2023 to a low of $3.0 million in Q4 2025.
• A 4-year average of $3.5 million and a median of $3.5 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability grew 5.74% in 2023 and fell 21.81% in 2024, its largest moves.
• ProQR Therapeutics' Non-Current Deferred Tax Liability stood at $3.8 million in 2022, then gained by 5.74% to $4.0 million in 2023, then dropped by 21.81% to $3.2 million in 2024, then declined by 4.8% to $3.0 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.0 million, $3.2 million, and $4.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison